Get started
Avacta at Key Level Avacta Group - Short Term - We look to Sell at 99.10 (stop at 112.85) Preferred trade is to sell into rallies. Previous support level of 105.00 broken. 50 1day EMA is at 100.00. Previous support at 105.00 now becomes resistance. Trading close to the psychological 100.00 level. Further downside is expected although we prefer to set shorts at our bespoke resistance levels at 105.00, resulting in improved risk/reward. Our profit targets will be 51.65 and 33.70 Resistance: 105.00 / 130.00 / 150.00 Support: 70.00 / 50.00 / 40.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
LSE:AVCTShort
by Saxo
Lloyds Bank: Buying the DipLloyds Bank - Short Term - We look to Buy at 50.06 (stop at 48.36) Preferred trade is to buy on dips. Previous resistance, now becomes support at 50.00. 50 1day EMA is at 49.80. The 50% Fibonacci retracement is located at 50.18 from 44.36 to 56.00. This move is expected to continue and we look to set longs at good risk/reward levels. Our profit targets will be 55.99 and 57.95 Resistance: 56.00 / 60.00 / 65.00 Support: 50.00 / 47.50 / 45.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
LSE:LLOYLong
by Saxo
GSK Glaxo Smith Kline - Multi Year Lows, A Bargain To Be Bought?GSK is trading around the multi year lows having bounced off of the long term support zone at 1300. I think this is a relative bargain at these levels with GSK being one of the Big Pharma Companies that is still trading way below the starting price for the year. Pfizer, Johnson & Johnson and Roche are all either positive or around net zero YTD. Novartis is trading slightly lower and so is Merck and Co but not to the extent of GSK making it a bargain in the big Pharma world. Dividend Yield is current around 5.3% which is high enough to warrant it being a good income stock even if the share price was to remain flat for the next 5 years. Upside targets are at 1720 which is the next major price resistance zone and and 1850 which is the 18 year highs (formed in 2019). There is a chance that price could fall back down to 1300 or even the multi year lows at 1235 which would make for a real bargain. But even at the current price of 1378.00 I think over the next 5 years this is a good stock to hold.
LSE:GSKLong
by DOAFK